Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Wednesday, November 18th. Analysts expect the company to post earnings of ($1.24) per share and revenue of $1.01 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 7:00 AM ET.
Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.41). The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $10.00 million. On average, analysts expect Zenas BioPharma to post ($6.23) EPS for the current fiscal year and ($4.99) EPS for the next fiscal year.
Zenas BioPharma Price Performance
ZBIO opened at $28.01 on Monday. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -2.97 and a beta of -0.88. Zenas BioPharma has a fifty-two week low of $13.50 and a fifty-two week high of $44.60. The company’s 50-day moving average price is $28.58 and its 200 day moving average price is $25.35. The company has a quick ratio of 9.42, a current ratio of 9.42 and a debt-to-equity ratio of 1.88.
Analysts Set New Price Targets
A number of equities analysts have commented on ZBIO shares. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, October 28th. Morgan Stanley assumed coverage on Zenas BioPharma in a research report on Tuesday, October 20th. They set an “equal weight” rating and a $32.00 price target on the stock. Guggenheim reissued a “buy” rating and issued a $55.00 price target on shares of Zenas BioPharma in a report on Wednesday, September 30th. HC Wainwright restated a “buy” rating and set a $44.00 price objective on shares of Zenas BioPharma in a research report on Tuesday, October 13th. Finally, Wedbush restated an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a research report on Wednesday, September 30th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zenas BioPharma has an average rating of “Moderate Buy” and an average target price of $46.71.
Read Our Latest Analysis on ZBIO
About Zenas BioPharma
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business. Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.
Read More
- Five stocks we like better than Zenas BioPharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
